Möller H J
Psychiatrische Klinik der Ludwig-Maximilians-Universität München.
Nervenarzt. 2000 May;71(5):345-53. doi: 10.1007/s001150050568.
The results of controlled studies of the efficacy of the new atypical neuroleptics in treating negative symptoms show that these antipsychotics have a more pronounced effect on negative symptoms in acute schizophrenic patients than the classical neuroleptics. Supplementary complex statistical analyses substantiate that the increased efficacy of the atypical neuroleptics in treating negative symptoms can only partially be explained by indirect effects of better extrapyramidal tolerability, better effects on productive psychotic symptoms, etc. Instead, it is due largely to the stronger direct effect of these atypical neuroleptics. Clinical studies to evaluate their efficacy in chronic schizophrenic patients with stable, predominantly negative symptoms are still mostly lacking. First results support the presumption that atypical neuroleptics have a direct effect. Parallel to the evaluation of the new atypical neuroleptics, important progress has been made in the methodology of clinical studies in this area.
对新型非典型抗精神病药物治疗阴性症状疗效的对照研究结果表明，这些抗精神病药物在治疗急性精神分裂症患者的阴性症状方面比传统抗精神病药物有更显著的效果。补充性综合统计分析证实，非典型抗精神病药物在治疗阴性症状方面疗效增加，只能部分地通过更好的锥体外系耐受性的间接作用、对阳性精神病性症状更好的疗效等来解释。相反，这主要是由于这些非典型抗精神病药物更强的直接作用。目前仍大多缺乏评估它们对具有稳定的、以阴性症状为主的慢性精神分裂症患者疗效的临床研究。初步结果支持非典型抗精神病药物具有直接作用这一推测。在对新型非典型抗精神病药物进行评估的同时，该领域的临床研究方法也取得了重要进展。
